Digital ad verification company Integral Ad Science (NASDAQ:IAS) reported Q3 CY2025 results , with sales up 15.6% year on year to $154.4 million. Its GAAP profit of $0.04 per share was 42.2% below ...

In the last three months, 4 analysts have published ratings on Integral Ad Science Holdi (NASDAQ:IAS), offering a diverse range of perspectives from bullish to bearish. The following table summarizes ...

In the latest quarter, 4 analysts provided ratings for Integral Ad Science Holdi (NASDAQ:IAS), showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their ...

Revenue for Q4 2024 grew 14% to $153 million, with an adjusted EBITDA margin of 40%. Full-year 2024 revenue reached $530.1 million, marking a 12% increase with a 36% adjusted EBITDA margin. CEO Lisa ...

A few months after SK Life Science began rolling out a road trip-themed TV commercial for its antiseizure medication Xcopri, the FDA is attempting to put the brakes on the ad. The regulator late last ...

"Road to Reduction" Begins Airing Today Raising Awareness of XCOPRI® (cenobamate tablets) CV and the Journey to Seizure Management for People Living with Epilepsy PARAMUS, N.J., May 19, 2025 ...

NEW YORK (AP) — NEW YORK (AP) — Integral Ad Science Holding Corp. (IAS) on Tuesday reported third-quarter profit of $7 million. The New York-based company said it had profit of 4 cents per share.

Novacap has agreed to acquire Integral Ad Science Holding Corp. in a deal that values the advertising analytics company at about $1.9 billion. The Canadian buyout firm will pay $10.30 a share in cash ...